ARCT News and Press, Arcturus Therapeutics Ltd. From 08/31/22

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to f...

New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Six months after booster dose of ARCT-154: BA.1: GMFR = 22 to 52; Titer = 674 to 1524 BA.2: GMFR = 25 to 55; ...

Raymond James has downgraded Arcturus Therapeutics ( NASDAQ: ARCT ) to underperform from market perform citing setbacks for vaccines for COVID-19, ornithine transcarbamylase deficiency, and cystic fibrosis. The firm does not have a price target. Analyst Steven Seedhous...

Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financial Officer Pad Chivukula - Chief Scientifc Officer and Chief O...

Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q2 GAAP EPS of -$0.82 beats by $1.04 . Revenue of $27.09M (+1254.5% Y/Y) beats by $24.58M . Company’s cash balance totaled $283.5 million as of June 30, 2022, compared to a cash balance of $370.5 mill...

New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA.1 and BA.2 at Day 91 New cold chain data for Arcturus’ lyophilized vaccine platform shows favorable stability, shipping, a...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

Gainers: Inter &  ( INTR ) +34% . Cytokinetics ( CYTK ) +6% . MSP Recovery ( MSPR ) +6% . Ocular Therapeutix ( OCUL ) +5% . Kirkland's ( KIRK ) +5% . Losers: Microvast Holdings ( MVST ) -7% . Virgin O...